2026-04-17T19:27:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4741222025-08-31T17:00:11Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Laguno Centeno, Montserrat author Von Wichmann, Miguel Ángel author van den Eynde, Eva author Navarro, Jordi author Cifuentes, Carmen author Murillas, Javier author Veloso Esteban, Sergio author Martínez-Rebollar, María author Guardiola Tey, Jose Maria author Jou, Antoni author Gómez-Sirvent, J.L. author Cervantes, Manuel author Pineda, Juan A. author López-Calvo, Soledad author Carrero, Ana author Montes, Maria Luisa author Deig, Elisabet author Tapiz, A. author Ruiz-Mesa, Juan Diego author Cruceta, Anna author de Lazzari, Elisa author Mallolas Masferrer, Josep author Universitat Autònoma de Barcelona author 2016 Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferon-free therapies are not available yet. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients : final results of the Spanish BOC HIV-HCV Study